荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02509 荃信生物-B

交易中 08-18 15:20:46

17.540

-0.410

-2.28%

最高18.080	最低17.400	成交量16.92万
今开17.960	昨收17.950	日振幅3.79%
总市值39.11亿	流通市值39.11亿	总股本2.23亿
成交额302.06万	换手率0.08%	流通股本2.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":17.54,"timestamp":1787037359122,"preClose":17.95,"halted":0,"volume":169200,"delay":0,"changeRate":-0.022841225626740957,"floatShares":223000000,"shares":223000000,"eps":1.6394111695034903,"marketStatus":"交易中","change":-0.41,"latestTime":"08-18 15:20:46","open":17.96,"high":18.08,"low":17.4,"amount":3020562,"amplitude":0.037883,"askPrice":17.55,"askSize":1600,"bidPrice":17.4,"bidSize":800,"shortable":3,"etf":0,"ttmEps":1.63442084841164,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787040600000},"marketStatusCode":2,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":17.95,"openAndCloseTimeList":[[1787016600000,1787025600000],[1787029200000,1787040000000]],"volumeRatio":1.030485,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"1108795750","title":"荃信生物-B（02509）拟于8月19日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1108795750","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108795750?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:36","pubTimestamp":1786091801,"startTime":"0","endTime":"0","summary":"江苏荃信生物医药股份有限公司（02509，以下简称“荃信生物-B”）8月7日公告称，公司董事会决定于2026年8月19日（星期三）召开会议，届时将审议并批准本集团截至2026年6月30日止六个月的中期业绩及其发布事宜，并处理其他相关事项。\n公告显示，截至公告日，公司董事会成员包括：董事会主席兼执行董事裘霽宛先生，执行董事吴亦亮先生及林伟栋先生；非执行董事余熹先生及吴志强先生；独立非执行董事冯志伟先生、邹忠梅博士及凌建群博士。\n公司表示，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并不对其准确性或完整性作出任何声明，也不承担因依赖该公告内容而引致的任何损失责任。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166349659","title":"荃信生物-B发布7月股份变动月报，股本维持227,071,600元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166349659","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166349659?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:00","pubTimestamp":1786003254,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年8月6日披露了截至2026年7月31日止的月度证券变动报告。公告显示，公司法定注册股本维持227,071,600元，与上月末一致。本月内，荃信生物-B普通股H股已发行股份由上月底结存的223,381,800股下降至223,369,200股，减少12,600股；同时公司库存股份增加12,600股，从3,689,800股升至3,702,400股。公司确认上述变动后已发行股份总数继续维持在227,071,600股不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655636655","title":"荃信生物：QX027N注射液两项适应症获临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2655636655","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655636655?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:01","pubTimestamp":1785499260,"startTime":"0","endTime":"0","summary":"7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828550155.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828550155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MDTX","BK1161","02509","PSYK","IBBQ","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199457602","title":"荃信生物-B（02509）长效双抗QX027N获COPD及CRSwNP临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1199457602","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199457602?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:20","pubTimestamp":1785496838,"startTime":"0","endTime":"0","summary":"2026年7月31日，江蘇荃信生物醫藥股份有限公司发布自愿公告称，其自主研发的长效双特异性单克隆抗体QX027N注射液已获得中国国家药品监督管理局药品审评中心临床试验默示许可，拟用于治疗慢性阻塞性肺疾病和慢性鼻窦炎伴鼻息肉，受理号分别为CXSL2600561和CXSL2600560。该项目在特应性皮炎及哮喘之后新增两项呼吸系统相关适应症。公司介绍，该候选药物旨在为哮喘、COPD、AD及CRSwNP等免疫炎症类疾病提供更深层次且更持久的疾病控制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156603396","title":"荃信生物-B（02509.HK）旗下QX027n获两项临床试验批件，剑指COPD与慢性鼻窦炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1156603396","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156603396?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:18","pubTimestamp":1785496736,"startTime":"0","endTime":"0","summary":"荃信生物-B（QYUNS-B）近日宣布，其研发管线中的核心产品——QX027n，已成功获得两项临床试验批准。这两项批件分别针对慢性阻塞性肺疾病（COPD）以及慢性鼻窦炎两大适应症。\n这一进展标志着该药物在呼吸系统及耳鼻喉领域迈出了关键一步。COPD作为一种常见且严重的肺部疾病，患者群体庞大；而慢性鼻窦炎同样困扰着数以百万计的人群，治疗方案仍有待优化。QX027n若能在此两个领域取得突破，无疑将为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363591","title":"荃信生物-B(02509.HK)：QX027N获得慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉两项适应症的临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363591","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655363591?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:18","pubTimestamp":1785496712,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860380","title":"荃信生物-B(02509)合作伙伴Caldera Therapeutics拟与Synlogic合并登陆纳斯达克 并同步募资 2.78 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860380","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655860380?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:06","pubTimestamp":1785326788,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B 公布，于2026年7月29日，公司合作伙伴Caldera Therapeutics,Inc与Synlogic,Inc.订立最终合并协议，以进行全股票交易合并。该合并将通过Caldera Therapeutics及Synlogic成为一家新成立的控股公司的全资附属公司而实现。完成后，合并并后的公司将以Caldera Therapeutics,Inc.的名称营运，并预期于纳斯达克资本市场以股票代码“CALD”进行交易。该私募融资仅由CalderaTherapeutics完成。Synlogic股东于拟议合并完成时将拥有的合并后公司所有权百分比将根据Synlogic于紧接完成日期前的估计现金净额进行调整。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SYBX","BK1161","BK4139","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129909769","title":"荃信生物-B：合作方Caldera擬與Synlogic合併赴美上市並獲2.78億美元私募支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1129909769","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129909769?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:00","pubTimestamp":1785326448,"startTime":"0","endTime":"0","summary":"2026年7月29日，荃信生物-B发布自愿公告，披露其合作伙伴Caldera Therapeutics, Inc.已与Synlogic, Inc.签署最终合并协议，双方将通过全股票交易方式合并为新设控股公司的全资子公司。合并完成后，新公司将沿用“Caldera Therapeutics, Inc.”名称，并预计以股票代码“CALD”在纳斯达克资本市场挂牌交易。为配合拟议合并，Caldera Therapeutics已获一批医疗健康机构投资者及共同基金承诺认购，计划在同步私募融资中募集约2.78亿美元。Synlogic股东的最终持股比例将根据交易完成前其估计现金净额进行调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186215746","title":"荃信生物-B回购1000股股份，耗资约1.60万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186215746","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186215746?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:32","pubTimestamp":1784280730,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年7月17日发布公告，披露公司于香港联交所场内回购1000股普通股H股。该批股份占回购前已发行股本的约0.00045%，每股回购价为每股15.99港元，涉资总额约1.60万港元。本次回购股份将被持作库藏股。公告显示，经本次变动后，公司已发行股份总数仍为227,071,600股，其中在外流通股数为223,369,200股，库藏股数则增至3,702,400股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B回购1000股股份，耗资约1.60万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652401327","title":"荃信生物-B(02509)7月17日耗资约1.6万港元回购1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652401327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652401327?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:30","pubTimestamp":1784280616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)公布，2026年7月17日耗资约1.6万港元回购1000股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180232421","title":"荃信生物-B回购3,000股，耗资约4.52万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180232421","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180232421?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:26","pubTimestamp":1783592809,"startTime":"0","endTime":"0","summary":"江苏荃信生物医药股份有限公司于2026年7月9日发布公告，称公司当日通过香港联交所场内回购3,000股H股，占回购前已发行股本的约0.001343%。本次回购价格为每股15.08港元，总耗资约4.52万港元。公告显示，回购完成后，公司已发行股本总数仍为227,071,600股，其中不含库存股份的已发行股本由223,373,200股下降至223,370,200股，库存股份数量由3,698,400股增至3,701,400股。本次回购后，公司在新股发行及库存股份出售或转让方面将适用的暂止期截至2026年8月8日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B回购3,000股，耗资约4.52万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650237739","title":"荃信生物-B(02509)7月9日斥资约4.52万港元回购3000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650237739","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650237739?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:23","pubTimestamp":1783592617,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年7月9日该公司斥资约4.52万港元回购3000股，回购价格为每股15.08港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174667974","title":"荃信生物-B：7月8日回购600股，耗资约9,420港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174667974","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174667974?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:37","pubTimestamp":1783507076,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年7月8日根据股份回购授权，在香港联合交易所场内回购600股普通股，约占当日公司现有已发行股本的0.00027%，每股回购价格为15.70港元，合计耗资9,420港元。公告日期为2026年7月8日。本次回购完成后，截至2026年7月8日，荃信生物-B的已发行股本总数仍为227,071,600股，其中流通股数量减少至223,373,200股，库藏股数量增至3,698,400股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B：7月8日回购600股，耗资约9,420港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174266156","title":"荃信生物-B：7月7日回购8000股，耗资约12.56万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174266156","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174266156?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:02","pubTimestamp":1783422137,"startTime":"0","endTime":"0","summary":"2026年7月7日，江苏荃信生物医药股份有限公司发布翌日报表公告，披露于当日通过香港联交所场内回购普通股（H股）8,000股，占回购前已发行股本约0.0036%。每股回购价为15.70港元，涉资约12.56万港元。截至本次回购后，公司累计根据该授权购回股份数量为989,600股，占授权获通过当日已发行股本总数的0.4411%。公司方面确认已遵守香港联合交易所有限公司证券上市规则的相关规定。本次公告由董事会秘书和联席公司秘书胡衍保签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荃信生物-B：7月7日回购8000股，耗资约12.56万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981486","title":"荃信生物-B(02509.HK)7月7日耗资12.56万港元回购8000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981486","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649981486?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:55","pubTimestamp":1783421743,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113868491","title":"荃信生物-B更新6月股份变动月报表，股本总量保持227,071,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113868491","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113868491?lang=zh_cn&edition=full","pubTime":"2026-07-07 09:11","pubTimestamp":1783386713,"startTime":"0","endTime":"0","summary":"2026年7月7日，江苏荃信生物医药股份有限公司公布2026年6月股份变动月报表，披露了截至2026年6月30日的股本结构及相关变动情况。根据公告显示，荃信生物-B的法定及注册股本本月维持不变，仍为人民币227,071,600元。期末已发行股份为223,381,800股，较上月底的224,363,400股减少981,600股；同时，库藏股份从2,708,200股增加至3,689,800股，总股本保持在227,071,600股。该等回购股份暂未注销，全部被作为库藏股份持有。公告由董事会秘书和联席公司秘书胡衍保签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617234","title":"港股异动 | 荃信生物-B(02509)涨超8% CLD-423注射液获批临床 公司创新性管线出海授权陆续达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617234","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649617234?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:20","pubTimestamp":1783304433,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超8%，截至发稿，涨8.12%，报16.65港元，成交额144.38万港元。消息面上，近日，CDE官网显示，荃信生物申报的CLD-423注射液获批临床，拟开发治疗克罗恩病。公开资料显示，QX030N/CLD-423是一款双特异性抗体，靶向经临床验证的IL-23p19和TL1A通路，拟开发用于治疗炎症性肠病及其他免疫性和炎症性疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161","BK4588","BK4585","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649172316","title":"港股异动 | 荃信生物-B(02509.HK)涨超8% CLD-423注射液获批临床 公司创新性管线出海授权陆续达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2649172316","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649172316?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:20","pubTimestamp":1783304433,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648574371","title":"港股异动 | 荃信生物-B(02509.HK)最高涨超7% 收购赛孚士强化内部协同效应 加速旗下QX002N等核心产品审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2648574371","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648574371?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:09","pubTimestamp":1782972569,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160149677","title":"荃信生物-B：6月30日回购3,200股，耗资约4.58万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160149677","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160149677?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:45","pubTimestamp":1782819942,"startTime":"0","endTime":"0","summary":"2026年6月30日，荃信生物-B发布公告，披露公司于当日在香港联交所场内回购3,200股H股，占回购前公司已发行股本223,385,000股的约0.0014%。本次回购价格介乎每股14.23港元至14.50港元，累计耗资约45,812.16港元。回购后，公司已发行股本维持在227,071,600股，其中库存股增至3,689,800股。公告显示，本次回购依据2026年5月29日通过的购回授权进行。根据授权，公司可回购的股份总数为22,436,340股，至今已回购股份的累计数量为981,600股，占前述授权获批时已发行股本约0.4375%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B：6月30日回购3,200股，耗资约4.58万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.1226},{"period":"3month","weight":0.1219},{"period":"6month","weight":-0.1252},{"period":"1year","weight":-0.2008},{"period":"ytd","weight":-0.0442}],"compareEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":0.0363},{"period":"3month","weight":-0.0134},{"period":"6month","weight":-0.0469},{"period":"1year","weight":0.0072},{"period":"ytd","weight":-0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事自身免疫及过敏性疾病的生物疗法研发、制造及商业化的中国公司。该公司专注于皮肤、风湿、呼吸道及消化道疾病。该公司的产品主要包括赛乐信、奥托奇拜单抗，以及鲁塞奇塔单抗等。该公司在国内和国外市场开展业务。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}